An observational study in Pulmonary Arterial Hypertension and Diffuse Interstitial Lung Disease, sponsored by Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-08.
Sponsored by Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires · Observational
HYPID study is an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided catheterization. The primary aim of the study is to identify prognostic factors.
Pre capillary pulmonary hypertension (PH) may be present in patients with diffuse interstitial lung disease.
In this context, PH represents an important factor of morbidity and mortality for these patients.
One of the purposes of HYPID is to determine predictive factors of mortality within this cohort of patients.
In order to reach that aim,the study includes an evaluation based on exams conducted for the routine follow-up of patients. Each patient will be followed during 2 years at least.
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's enrollment of 224 is above the median of 157 across 929 observational studies indexed under Lung Diseases.
Browse Lung Diseases studies →Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with pre capillary pulmonary hypertension and interstitial lung disease at HRCT
Exclusion Criteria:
Overall survival
Determine predictive factors of mortality
Time frame: 2 years
Progression-free survival (1)
Determine cause of death
Time frame: 2 years
Progression-free survival (2)
Determine survival and time to worsening
Time frame: 2 years
Progression-free survival (3)
Analyse clinical, functional respiratory, hemodynamic features and changing characteristics of pulmonary hypertension
Time frame: 2 years
Progression-free survival (4)
Document the efficacy of PH specific treatment
Time frame: 2 years
Progression-free survival (5)
Evaluate the level of pulmonary arterial hypertension and compare the functional characteristics of patients with moderate or severe pulmonary hypertension
Time frame: 2 years
Progression-free survival (6)
Analyse clinical, functional respiratory, hemodynamic features and changing characteristics of pulmonary hypertension
Time frame: 2 years
Plan to share: Undecided
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires